摘要
目的研究CYFRA21-1,NSE和SA在肺癌诊断,疗效监测和预后观察的临床应用价值。方法213例肺癌,39例肺部良性疾病的住院和门诊病人应用链霉亲和素(SA)一生物素(B)包被技术检测CYFRA21-1血清水平;利用ELISA法检测NSE的血清水平;终点法检测唾液(SA)血清水平。结果肺癌组SYFRA2H,NSE,SA水平为6.95±7.47ng/ml,17.84±17.06ng/ml,658±122.64ug/ml,对照组为1.91±0.76ng/ml,8.17±2.82ng/ml,510±89.26ng/ml.(P<0.01)差异显著,肺癌阳性率分别为57.2%、46.4%、68.0%、CYFRA21-1对肺鳞癌检测灵敏度最高为76.3%,NSE以小细胞肺癌为最灵敏是81.4%,SA检测无病理类型之分,联合检查普查以三者联合为佳,术后、放疗、化疗后以CYFRA21-1+SA或NSE+SA为最好。结论CYFRA21-1、NSE、SA不同组合的联合检测,能有效地提高各种病理类型肺癌的敏感性,诊断准确性。为临床提供最有效的诊断和治疗依据。
Objective To study the clinical significant of CYFRA21-1,NSE and SA in the diagnosis,monitoring of curative effect and prognositic observation of lung cancer.Method The level of CYFRA21-1,NSE and SA in serum were examined using Streptavidin-Biotin-Avidin-coating teqnolege ELISA and Endpoint method separately in 213 cases of lung cancer,39 cases of benign lung diaeases.Results The level of CYFRA21-1,NSE and SA were 6.95±7.47ng/ml,17.B4±17.06ng/ml,658±122.64ug/ml in lung cancer group,They were 1.91±0.76ng/ml,8.17±2.82ng/ml,510±89.26ng/ml in contrast group.It has remakble diffrence(P<0.01).The positive rate in lung cancer were 57.2%、46.4% and 68.0% separately.The sensitivity of CYFRA21-1 in squamous cancer of lung was highest(76.3%),For small cell 1ung cancer,the NSE was most sensitive,it was 81.4%,but the level of SA was no diffrence in different pathological type.Conclusion Different combined examination of CYFRA21-1,NSE and SA could effectively increase the sensitivity and accuracy of diagnosis for lung cancer with various pathogogical type.it could provide most effective basis for the diagnosis and treatment of lung cancer.
出处
《医学检验与临床》
2006年第2期26-28,共3页
Medical Laboratory Science and Clinics
